Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Rhythm Pharmaceuticals Q2 2024 GAAP EPS $(0.55) Beats $(0.71) Estimate, Sales $29.078M Beat $28.789M Estimate

Author: Benzinga Newsdesk | August 06, 2024 07:01am
Rhythm Pharmaceuticals (NASDAQ:RYTM) reported quarterly losses of $(0.55) per share which beat the analyst consensus estimate of $(0.71) by 22.54 percent. This is a 32.93 percent increase over losses of $(0.82) per share from the same period last year. The company reported quarterly sales of $29.078 million which beat the analyst consensus estimate of $28.789 million by 1.00 percent. This is a 51.28 percent increase over sales of $19.221 million the same period last year.

Posted In: RYTM


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist